

Life Sciences Discovery Fund Authority
Draft Public Board Meeting Minutes
Tuesday, September 18, 2007 | 8:30a-6:00p
LSDF Office at 2324 Eastlake Ave E, Ste 501, Seattle WA

Trustees Present: Lura Powell, Rita Colwell (via telecon 2p-4:45p), Jim Cook, Sen Jerome Delvin, Tony Hey (in person and via telecon for concluding public session), Gov Gary Locke, Sen Chris Marr, Rep Jeff Morris (via telecon 2p-5p), Bruce Montgomery, Rep Skip Priest, and Cheryl Scott

Others Attending in Person: Lee Huntsman, John Des Rosier, Mark Hertle, Kelly Moutsos, Alden Jones, Brenda Stav, Rich Murphy, Pamela Anderson, Prof David Boerner, Ed Derrick.

Others Attending Concluding Public Session: Brad Jurkovich, Kara Durbin (via telecon), Dennis Dyck (via telecon), Dimitri Christakis (via telecon), Todd Christensen (via telecon), Gail Dykstra, Alan Yen, Andrea James, TVW staff.

MINUTES

PUBLIC SESSION

Welcome and Approval of Minutes – Board welcomed newly appointed trustee Senator Chris Marr replacing Senator Lisa Brown; new LSDF Grants Administrator Kelly Moutsos; new LSDF/WBBA receptionist Brenda Stav; AAAS representative Ed Derrick; and conflict of interest expert/consultant and Seattle University professor David Boerner. The Board approved minutes from the July 17, 2007 board meeting.

Other Business

- **Donor Conflict of Interest** (Anderson) – LSDF has a conflicts policy to ensure that Board members, staff, and independent reviewers disclose beneficial personal, financial and volunteer interests in applicants or co-applicants and recuse themselves from consideration of proposals when they have a disqualifying conflict. A similar policy is needed regarding donor organizations that may, at some time, be applicants or co-applicants for funding. The following motion was passed by the Board: “In determining the merit of proposals, the Board will not consider the fact that a donor, or entity affiliated with a donor, is an applicant for a grant. To assist the Board in complying with this policy, the Board will invite Seattle University professor Boerner to join the executive session on September 18, 2007, for the express purpose of observing the discussion, being attentive to conflicts issues, especially related to the status of applicants as donors, and advising the Board about appropriate ways to resolve any conflict of interest issues that arise.”
- **Fund Raising** (Huntsman) – \$3.6M raised to date, an additional \$125K will trigger the Allen matching gift and bring the total 07-01 pool to \$6M. For purposes of the September 18, 2007 selection process, fundraising team recommended board plan on \$6M as the amount available to award. If necessary, funding gap would be bridged by tobacco settlement revenue.
- **Day’s Schedule** (Powell) – Overview of day’s agenda provided, noting approximate timing of public and executive sessions.
- **Media Coverage** (Huntsman) – Advance outreach to media across the state via personal contact by Murphy and editorial boards at *Tri Cities Herald*, *Spokesman Review*, *Seattle Times*, *Seattle PI*, and *Puget Sound Business Journal*.
- **Expert Review/AAAS** (Derrick) – Ed Derrick, AAAS representative, provided an overview of expert review process including a national perspective.

Executive Session – 07-01 Proposal Review and Discussion (9a-5:15p)

Public Session (5:20p start)

Please note, video/audio of this segment available at TVW Web site

<http://www.tvw.org/media/mediaplayer.cfm?evid=2007090132&TYPE=V&CFID=826599&CFTOKEN=9b9645138f21cd57-6BE5BE57-3048-349E-4E13935EAA1022AE&bhcp=1>

- **07-01 Award Announcement** (Powell) – Overall 07-01 competition goals restated for the record: promote competitiveness, improve health and health care, foster economic growth. 07-01 donors acknowledged (Amgen, Bill & Melinda Gates Foundation, Paul G Allen Family Foundation, Microsoft, Regence BlueShield, Safeco). Expert review (by AAAS) and selection process described. Grant recipients (subject to grant agreement negotiations with applicant organizations) announced as follows by Powell:

William Hagopian, Pacific Northwest Research Institute, \$981,381.

Project title: Diabetes Evaluation in Washington Study

Project focus: Type 1 (juvenile) diabetes is one of the leading chronic childhood diseases in the U.S., leading to a variety of complications that include blindness, renal failure and lower extremity amputation. This study expects to develop a public health-based pediatric screening program to identify children at risk for type 1 diabetes prior to disease onset. The program is expected to minimize the impact and cost of later disease onset.

Cornelius Ivory, Washington State University, \$750,000.

Project title: Rapid Fingerprinting of Cardiac Biomarkers

Project focus: Over 1.2 million new and recurrent heart attacks are diagnosed in the U.S. every year. Better treatment could be provided to affected individuals if diagnoses could be made more quickly. The goal of this research study is to develop a portable microchip test for rapid point-of-care diagnosis of acute cardiac distress in an emergency-care situation or for long-term prognosis of cardiovascular disease before the emergence of symptoms. The small size, ease of use and rapid response of the test will allow it to be administered in an emergency situation, leading to a more accurate diagnosis and saving lives.

David Flum, University of Washington, \$1,354,322.

Project title: Surgical Care and Outcomes Assessment Program

Project focus: Data indicate that there is significant variation between different hospitals in the safety and outcomes of nearly every technology-based medical procedure. With this LSDF grant, Dr. Flum will expand the Surgical Care and Outcomes Assessment Program (SCOAP) to an additional 30 hospitals across Washington. By benchmarking member hospitals against each other in the use of various technologies, SCOAP reduces the inappropriate use of emerging health-care technologies to improve their use, effectiveness, and safety.

David Newell, Swedish Medical Center, \$169,532.

Project title: IHUT (Intracranial and Intraventricular Hemorrhage with Ultrasound Enhanced Thrombolysis)

Project focus: Intracerebral hemorrhage (hemorrhagic stroke) occurs in over 100,000 Americans per year and has no effective treatment. It is fatal in 30% to 50% of all occurrences and the majority of survivors have significant cognitive and motor disability. This study will use catheter-delivered ultrasound and medication (rTPA) to treat intracranial and intraventricular hemorrhage following hemorrhagic stroke. This method is expected to reduce brain injury, increase patient survival rates, and improve the chances for full patient recovery.

Daniel T. Chiu, University of Washington, \$760,000.

Project title: Monitoring Breast Cancer Metastasis and Treatment Efficacy

Project focus: Breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in Washington. The research in this study is aimed at monitoring circulating tumor cells and tumor DNA in patient blood using a chip-based device. This work is expected to result in a low-cost method for monitoring breast cancer prognosis, treatment efficacy and early diagnosis.

Philip Jeffrey Hummel, Qualis Health, \$530,000.

Project title: Applying Health Information Technology to Improve Medication Management
Project focus: Inaccurate medication reconciliation across transitions of care results in adverse outcomes including medical errors, unnecessary direct costs, and waste of provider and patient time in integrating prescription data from multiple providers. The objective of the proposed study is to integrate a series of existing technologies to deliver real-time patient medication history information to health care practitioners caring for patients in ambulatory and inpatient settings, and to evaluate the impact of this health information exchange on adherence to medication reconciliation quality measures, on satisfaction, and on cost-effectiveness of medication use. The study is expected to result in improved chronic illness care.

- **Conflicts of Interest Policy Statement (Anderson)** –The following board conflicts summary was read by Anderson:
“At the beginning of the Executive Session, the trustees were reminded of their obligations under their conflicts policy, which requires the disclosure of beneficial and volunteer interests in applicants or co-applicants. The Board determined that any collaborator interest should be assessed on a case by case basis with reference to the nature of the relationship. The trustees were polled as to their conflicts of interest, with the following results:
Gov. Gary Locke is a member of the Fred Hutchinson Cancer Research Center (FHCRC) board of trustees. Gov. Locke’s wife is on the board of Seattle Children’s Hospital and Regional Medical Center (Children’s). Gov Locke indicated his intention to recuse himself from the discussion of any proposal in which Children’s or the FHCRC are applicants or co-applicants. If a proposal in which Children’s or FHCRC is a collaborator is under consideration, staff will provide a summary of the collaborator’s interest.
Bruce Montgomery has a significant ownership interest in Gilead, a major vendor/developer of drugs for treating HIV. He indicated an intent to recuse himself from discussion and consideration of a proposal involving HIV treatment strategies.
Cheryl Scott is a former president of Group Health, a professional relationship that ended three years ago. After discussion with the Board, Cheryl decided to participate in the discussion of the Group Health Cooperative proposals but recuse herself from the vote. Cheryl also disclosed a volunteer relationship with the Association of Washington Public Health Districts. The Board decided that no recusal was in order. However, Ms. Scott indicated an intent to voluntarily recuse herself from any vote on the proposal.
Senator Chris Marr disclosed a position on the Group Health Foundation board. Although the Foundation is not an applicant, Sen. Marr will voluntarily recuse himself from a vote on any proposals by entities related to Group Health. Sen. Marr also disclosed a volunteer relationship on the board of the Institute for Systems Medicine (a co-investigator in a proposal to LSDF). The Board decided that recusal was not required.
Lura Powell disclosed that she owns 300 shares of Intel stock. Intel is a co-applicant in a proposal. The Board determined that due to this small ownership interest and attenuated benefit to Intel, recusal was not required. Lura also disclosed a personal interest in a proposal by the FHCRC. The Board determined that recusal was not required; however Lura expressed an interest to voluntarily recuse herself. Lura finally disclosed a past relationship with Kadlec Clinic for which the Board decided a recusal was in order.

Two Group Health proposals were discussed and unanimously denied by the trustees, after recusal by Cheryl Scott and Sen Chris Marr from the vote. One Children’s proposal was discussed and denied funding. Gov Gary Locke recused himself from the discussion.”

The other disclosed conflicts were unrelated to proposals that were discussed in the executive session, because none of those proposals met the threshold for consideration.

- **Governor’s Life Sciences Summit** (Powell) – Reminder that the Governor’s third Life Sciences Summit will be held September 27 at McCaw Hall from 8a-11a. LSDF 07-01 competition and awardees to be featured in part of the program.

*Respectfully submitted,
Lee Huntsman*